logo
logo
Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.

NASDAQ•CPRX
CEO: Mr. Richard John Daly M.B.A.
セクター: Healthcare
業種: Biotechnology
上場日: 2006-11-08
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.
連絡先情報
355 Alhambra Circle, Suite 801, Coral Gables, FL, 33134, United States
305-420-3200
www.catalystpharma.com
時価総額
$2.98B
PER (TTM)
13.7
34.6
配当利回り
--
52週高値
$26.58
52週安値
$19.05
52週レンジ
69%
順位32Top 23.6%
4.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025

財務ダッシュボード

Q3 2025 データ

売上高

$148.39M+15.30%
直近4四半期の推移

EPS

$0.43+16.22%
直近4四半期の推移

フリーCF

$32.44M-55.33%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine Months Net Income Growth Nine months net income $161.63M, up 49.7% from $107.95M in prior year period, showing strong profitability.
Total Revenues Increased Nine months total revenues $436.38M, significantly increased versus $349.91M recognized in the comparable 2024 period.
Strong Cash Position Maintained Cash and equivalents strong at $689.89M on September 30, 2025, providing ample liquidity for operations and strategy.
AGAMREE Sales Contribution AGAMREE net product revenue $81.79M for nine months 2025, reflecting successful post-launch commercial ramp activities.

リスク要因

FYCOMPA Generic Erosion FYCOMPA revenue declined $5.3M for nine months 2025 following May 2025 patent expiration and subsequent generic entry.
FIRDAPSE Litigation Uncertainty FIRDAPSE patent litigation against Hetero remains ongoing, creating uncertainty regarding generic market entry timing.
Reliance on Third-Party Supply Exclusive reliance on third-party contractors for manufacturing poses significant supply chain continuity risks.
Inventory Reserve Established Inventory reserve established at $0.5M for unsalable product, specifically slow-moving FYCOMPA inventory units.

見通し

New Share Repurchase Plan New $200M share repurchase program authorized through December 31, 2026, funded by existing cash resources.
Portfolio Expansion Focus Strategy focuses on acquiring near-term accretive, clinically differentiated products across rare disease therapeutic areas.
AGAMREE Manufacturing Transition Completing validation of U.S. manufacturing site for AGAMREE is expected by the end of calendar year 2026.
Continued Commercial Investment Expect substantial SG&A expenses to continue supporting FIRDAPSE and AGAMREE commercial expansion efforts.

同業比較

売上高 (TTM)

Apellis Pharmaceuticals, Inc.APLS
$1.02B
+42.1%
Amicus Therapeutics, Inc.FOLD
$598.70M
+21.3%
Kiniksa Pharmaceuticals International, plcKNSA
$597.97M
+55.7%

粗利益率 (最新四半期)

IDEAYA Biosciences, Inc.IDYA
99.5%
+0.0pp
Apellis Pharmaceuticals, Inc.APLS
94.7%
+11.7pp
Arcutis Biotherapeutics, Inc.ARQT
91.2%
+3.5pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
IBRX$6.46B-17.862.8%0.0%
CDTX$5.61B-18.6-60.1%0.4%
SRRK$4.86B-15.3-122.0%26.7%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.5%
緩やかな成長
4四半期純利益CAGR
-1.9%
収益性の安定
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年2月25日
|
EPS:$0.42
|
売上高:-
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月5日|
    売上高: $148.39M+15.3%
    |
    EPS: $0.43+16.2%
    予想を上回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月6日|
    売上高: $146.56M+19.4%
    |
    EPS: $0.43+22.9%
    予想を上回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $141.42M+43.6%
    |
    EPS: $0.47+135.0%
    予想を上回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年2月26日|
    売上高: $491.73M+23.5%
    |
    EPS: $1.38+106.0%
    予想を上回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $128.70M+25.3%
    |
    EPS: $0.37-227.6%
    予想を上回る

  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月7日|
    売上高: $122.71M+23.2%
    |
    EPS: $0.35-2.8%
    予想を上回る

  • Form 10-Q - Q1 2024

    会計期末: 2024年3月31日|提出日: 2024年5月8日|
    売上高: $98.51M+15.4%
    |
    EPS: $0.20-28.6%
    予想通り

  • Form 10-K - FY 2023

    会計期末: 2023年12月31日|提出日: 2024年2月28日|
    売上高: $398.20M+85.9%
    |
    EPS: $0.67-16.3%
    予想を上回る